1
|
Mollazadeh M, Mohammadi-Khanaposhtani M, Valizadeh Y, Zonouzi A, Faramarzi MA, Hariri P, Biglar M, Larijani B, Hamedifar H, Mahdavi M, Sepehri N. 2,4-Dioxochroman Moiety Linked to 1,2,3-triazole Derivatives as Novel α-glucosidase Inhibitors: Synthesis, In vitro Biological Evaluation, and Docking Study. CURR ORG CHEM 2020. [DOI: 10.2174/1385272824999200802181634] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
In this study, a novel series of 2,4-dioxochroman-1,2,3-triazole hybrids 8a-l
was synthesized by click reaction. These compounds were screened against α-glucosidase
through in vitro and in silico evaluations. All the synthesized hybrids exhibited excellent
α-glucosidase inhibition in comparison to standard drug acarbose. Representatively,
3-((((1-(3,4-dichlorobenzyl)-1H-1,2,3-triazol-4-yl)methyl)amino)methylene)chroman-2,4-
dione 8h with IC50 = 20.1 ± 1.5 μM against α-glucosidase, was 37-times more potent than
acarbose. Enzyme kinetic study revealed that compound 8h was a competitive inhibitor
against α-glucosidase. In silico docking study on chloro derivatives 8h, 8g, and 8i were
also performed in the active site of α -glucosidase. Evaluations on obtained interaction
modes and binding energies of these compounds confirmed the results obtained through in
vitro α-glucosidase inhibition.
Collapse
Affiliation(s)
- Marjan Mollazadeh
- School of Chemistry, College of Science, University of Tehran, Tehran, Iran
| | - Maryam Mohammadi-Khanaposhtani
- Cellular and Molecular Biology Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran
| | - Yousef Valizadeh
- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Afsaneh Zonouzi
- School of Chemistry, College of Science, University of Tehran, Tehran, Iran
| | - Mohammad Ali Faramarzi
- Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Parsa Hariri
- Department of Pharmaceutical Biotechnology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran
| | - Mahmood Biglar
- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Bagher Larijani
- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Haleh Hamedifar
- CinnaGen Medical Biotechnology Research Center, Alborz University of Medical Sciences, Karaj, Iran
| | - Mohammad Mahdavi
- Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
| | - Nima Sepehri
- Nano Alvand Company, Avicenna Tech Park, Tehran University of Medical Sciences, Tehran, 1439955991, Iran
| |
Collapse
|